

Pingarrón Santofimia, C; Álvarez Espinosa, Y; Hernández Aguado, J.J.; López Castejón, A.I; Soledad Martínez García, M; Blanco-Soler, C; et al.
Hosp. Quirón San José, Madrid; Hosp. Quirón Donostia, Donostia; Hosp. Infanta Leonor, Madrid; Ginecología Alcalá de Henares, Madrid; Hosp. Cima, Barcelona; J.S. Hospiten Roca, Las Palmas de Gran Canaria



METHODOLOGY

A Multicentre Prospective Observational Study with a Control Group in Real Clinical Practice.

POPULATION ASSESSED



Women aged 25-65 years with normal/ASCUS/LSIL cytology and PCR diagnosis of HR HPV+

Genotypes:

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 y 68



*44.1% (46% in Colpopix® and 36.4% in W&S) were vaccinated against HPV.




OBJECTIVE

To assess the efficacy of local treatment with carboxymethyl β -glucan and polycarbophil on the rate of **HPV infection negativisation**




6-MONTH RESULTS

Total negativisation of HR HPV+



Total HR HPV+ negativisation in the Colpopix® group was **DOUBLE (50.1%)** the 24% achieved in the W&S group at 6 months

HPV 16 negativisation



Negativisation of HPV 16 was **5 times greater (50.7%)** in the Colpopix® group than the W&S group patients (9.2%)

No adverse effects were reported during the study